Commercial success of radiopharmaceuticals depends on how well therapies align with real-world care delivery.
From treatment pathways to site capabilities, the transition from approval to routine use requires more than clinical validation.
This white paper examines the key factors shaping radiopharmaceutical commercialization, where adoption is influenced by infrastructure readiness, referral patterns, and how care is delivered in practice.
Key takeaways
- Why commercial adoption depends on more than clinical efficacy
- The role of site-of-care capabilities and treatment workflows in scaling use
- How referral networks and care pathways influence patient access
- What sponsors should consider to ensure commercial readiness early in development
See how these factors influence commercialization at scale in the full paper.
Offered Free by: Institute@Precision
See All Resources from: Institute@Precision
